Femasys Inc.
NasdaqCM:FEMY Stock Report
Femasys Dividends and Buybacks
Dividend criteria checks 0/6 Femasys does not have a record of paying a dividend.
Key information Total Shareholder Yield -47.8% Future Dividend Yield n/a Dividend Growth n/a Next dividend pay date n/a Ex dividend date n/a Dividend per share n/a Payout ratio n/a
Recent dividend and buyback updates
Show all updates
Femasys (NASDAQ:FEMY) Has Debt But No Earnings; Should You Worry? Oct 31
Femasys Inc. Receives U.S. FDA Clearance to Market FemChec, an Innovative Diagnostic Solution for Fallopian Tube Check Sep 11
Consensus revenue estimates fall by 40% Aug 15
New major risk - Financial position Aug 11
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 09
Shareholders May Be More Conservative With Femasys Inc.'s (NASDAQ:FEMY) CEO Compensation For Now Jul 05
Femasys Inc., Annual General Meeting, Jul 12, 2024 Jun 10
Consensus revenue estimates decrease by 17%, EPS upgraded May 16
Price target increased by 8.1% to US$10.00 May 12
New major risk - Financial position May 10
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind May 10
Consensus revenue estimates fall by 13% Apr 04
Health Check: How Prudently Does Femasys (NASDAQ:FEMY) Use Debt? Apr 03
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 31
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution Mar 07
New major risk - Share price stability Feb 09
Femasys Inc. Appoints Richard Spector as Chief Commercial Officer Feb 06
Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At UC Davis Medical Center, A Hub for Innovation and Groundbreaking Research in Health Care for Women Jan 26
Femasys Inc. Begins Fembloc Pivotal Trial Enrollment At University of Utah Jan 23
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine Dec 15 Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors Nov 23
Femasys Inc. Appoints Joshua Silverman as Director Nov 22
New major risk - Shareholder dilution Nov 19
Third quarter 2023 earnings: EPS and revenues miss analyst expectations Nov 17
Consensus revenue estimates fall by 11% Nov 16
New major risk - Revenue and earnings growth Nov 16
Femasys Inc. Successfully Completes the Stage 2 European Union (EU) Medical Device Regulation Oct 29
Here's Why We're Watching Femasys' (NASDAQ:FEMY) Cash Burn Situation Sep 27 Femasys Inc. Obtains Medical Device Establishment License from Health Canada Sep 01
New major risk - Revenue and earnings growth Aug 12
Femasys Inc. Designates Daniel Currie as its Chief Operating Officer Aug 11
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Aug 11
Femasys Inc. Announces FDA Approval of its IDE for the Pivotal Clinical Trial of FemBloc Permanent Birth Control, A Non-Surgical Alternative for Women Jun 28
Femasys Inc. Announces Management Changes Jun 16
Femasys' FemCath Intrauterine Catheter Receives Product Approval in Canada Jun 09
Femasys Receives a Notice from the Nasdaq Stock Market Regarding Minimum Bid Price Requirement Jun 03
Consensus EPS estimates upgraded to US$0.93 loss, revenue downgraded May 18
Femasys Inc., Annual General Meeting, Jun 21, 2023 May 16
First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind May 12
Femasys Inc.'s FemCerv Endocervical Tissue Sampler for Cervical Cancer Diagnosis Receives Product Approval in Canada May 05
Consensus EPS estimates fall by 32% Apr 06
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Mar 31
Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device Dec 20
Femasys Inc. Reports Encouraging Promotional Launch of Femcerv At AAGL Based on Positive Reception by Gynecologic Physicians and Surgeons Dec 13
Femasys Inc. Completes Over 25% of its Targeted Enrollment in its FemaSeed De Novo Trial Nov 30
Price target decreased to US$7.33 Nov 16
Third quarter 2022 earnings: EPS and revenues miss analyst expectations Nov 11
Femasys Inc. Provides Strategic Update on FemaSeed Pivotal Trial Design to Expedite Clinical Program Advancement Oct 21
Femasys Inc. Appoints Christine Thomas as Senior Vice President of Regulatory and Clinical Affairs, Effective October 10, 2022 Oct 13
Femasys Inc. Announces Enrollment Completion for Stage 2 Study of FemBloc for Permanent Birth Control Oct 07
Femasys Inc. Announces Commercial Availability of FemCerv® Sep 30
Femasys commercially launches Femcerv for cervical cancer screening Sep 29
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 12
Femasys GAAP EPS of -$0.22 beats by $0.01, revenue of $0.3M misses by $0.01M Aug 10
Femasys Inc. Announces Board Changes Jul 07
We Think Femasys (NASDAQ:FEMY) Needs To Drive Business Growth Carefully May 22
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind May 13
Femasys Inc. Appoints Dov Elefant to Chief Financial Officer, Effective February 28, 2022 Feb 25
Insufficient new directors Jan 01
Femasys: Revolutionizing Female Reproduction Jul 16
Independent Director recently bought US$172k worth of stock Jun 28
Femasys Inc. has completed an IPO in the amount of $34.45 million. Jun 19
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if FEMY's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if FEMY's dividend payments have been increasing.
Dividend Yield vs Market Femasys Dividend Yield vs Market
How does FEMY dividend yield compare to the market? Segment Dividend Yield Company (FEMY) n/a Market Bottom 25% (US) 1.3% Market Top 25% (US) 4.3% Industry Average (Medical Equipment) 1.7% Analyst forecast (FEMY) (up to 3 years) n/a
Notable Dividend: Unable to evaluate FEMY's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate FEMY's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate FEMY's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as FEMY has not reported any payouts.
Discover strong dividend paying companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
